Estey Elihu H, Giles Francis J, Beran Miloslav, O'Brien Susan, Pierce Sherry A, Faderl Stefan H, Cortes Jorge E, Kantarjian Hagop M
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA.
Blood. 2002 Jun 1;99(11):4222-4. doi: 10.1182/blood-2001-12-0174.
We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m(2) day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/microL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m(2) every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84%). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible.
我们对19例未经治疗的急性早幼粒细胞白血病（APL）患者给予吉妥单抗奥唑米星（“米哚妥林”；第1天或第5天9 mg/m²）和全反式维甲酸（ATRA）。有3例患者因白细胞（WBC）计数超过30000/μL还接受了伊达比星治疗。完全缓解（CR）时，患者接受8个疗程的米哚妥林（每4至5周9 mg/m²）和ATRA治疗；仅在持续或复发的聚合酶链反应（PCR）阳性时添加伊达比星。CR率为16/19（84%）。到目前为止接受检测的所有12例患者自CR日期起2至4个月时PCR均为阴性；随后评估的7例患者中无一例恢复为PCR阳性（CR后的中位随访时间为5个月，最长14个月）。米哚妥林耐受性良好。到目前为止，CR后疗程的中位数为5个，3例患者目前已接受8个CR后疗程，4例患者接受7个CR后疗程。米哚妥林在APL中似乎有活性，重复给药是可行的。
